HCP1904 1
Alternative Names: HCP1904-1; HCP1904-2; HCP1904-3Latest Information Update: 05 Oct 2023
At a glance
- Originator Hanmi Pharmaceutical
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Essential hypertension
Most Recent Events
- 08 Jun 2022 Hanmi Pharmaceutical plans a phase I trial in Healthy volunteers, in South Korea, In June 2022 (NCT05407220)
- 08 Nov 2021 Hanmi Pharmaceutical Company Limited initiates enrolment in a phase III trial for Essential Hypertension (Treatment-experienced) in South Korea (PO) (NCT05199129)
- 12 Sep 2021 Hanmi Pharmaceutical completes a phase I trial in Healthy volunteers in South Korea (NCT05191563))